Atlas Trials

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Clinical trial NCT03334487 · WITHDRAWN

Trial details

NCT number
NCT03334487
Sponsor
AbbVie
Status
WITHDRAWN
Phase
Phase 3
Study type
INTERVENTIONAL
Small Cell Lung Cancer
Start date
2018-03-15
Primary completion
2018-12-20
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.